6-sulfogalactose | 2152-84-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-sulfogalactose
• 英文别名: O⁶-sulfo-D-galactose；D-galactose 6-sulfate；D-Galactose-6-sulfat；D-galacto-2,3,4,5-Tetrahydroxy-6-sulfooxy-hexanal；Galactose 6-sulfate；[(2R,3S,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexyl] hydrogen sulfate
• CAS: 2152-84-3
• 化学式: C₆H₁₂O₉S
• 分子量: 260.222
• InChiKey: BCUVLMCXSDWQQC-KCDKBNATSA-N

物化性质

• 密度：
  1.841±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -3.8
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  170
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  6-sulfogalactose 在 盐酸 作用下， 以 水 为溶剂， 生成 口服葡萄糖
  参考文献：
  名称：

  On the desulphation of carbohydrate sulphates

  摘要：

  DOI：

  10.1016/0008-6215(83)88470-5
• 作为产物：
  描述：

  D-O¹,O²;O³,O⁴-diisopropylidene-galactitol 在 吡啶 、 环拉酸 作用下， 生成 6-sulfogalactose
  参考文献：
  名称：

  Nagasawa,K.; Yoshidome,H., Chemical and pharmaceutical bulletin, 1970, vol. 18, # 10, p. 2023 - 2027

  摘要：

  DOI：

文献信息

• POLY(PHOSPHOESTERS) FOR DELIVERY OF NUCLEIC ACIDS
  申请人：TRANSLATE BIO, INC.

  公开号：US20200277446A1

  公开（公告）日：2020-09-03

  Disclosed are polymers comprising the moiety A, which is a moiety of formula I: and pharmaceutically acceptable salts thereof, wherein R, R 1 , R 2 , L, n1 and n2 are as defined herein. These polymers are useful for delivering nucleic acids to subject. These polymers and pharmaceutically acceptable compositions comprising such polymers and nucleic acids can be useful for treating various diseases, disorders and conditions.

  揭示了包含A基团的聚合物，该基团是化学式I的基团：及其药用可接受的盐，其中R、R1、R2、L、n1和n2如本文所定义。这些聚合物对于将核酸传递给受试者是有用的。这些聚合物和包含这些聚合物和核酸的药用可接受组合物可用于治疗各种疾病、疾病和症状。
• Use of multivalent glycodendrimers to inhibit the activity of human immunodeficiency virus
  申请人：——

  公开号：US20040180852A1

  公开（公告）日：2004-09-16

  The present invention relates to compositions and methods for inhibiting the interaction of a ligand and receptor. In particular, compositions are methods are provided for inhibition of interaction between a virus, especially HIV, and a receptor. Inhibition of such ligand/receptor interaction is advantageous in inhibiting infection of a cell with a virus. Further, an inhibitor of ligand/receptor interaction serves as a standard in assays of inhibition in vitro or in vivo. In a particular embodiment, a composition according to the invention includes a compound having the formula: [(X)—(Y)] p -Z where X is 1 and where Q1 and Q2 are each independently H, a bond to Y, or a bond to Z, where at least one of Q1 or Q2 is a bond to Y or a bond to Z; where R1, R4, R6 and R8 are each H; R2, R3, and R5 are each independently OH, OSO3D, or OPO3D, and R7 is CH20H, CH2OSO3D or CH2OPO3D; where D is H or a cation selected from the group consisting of: alkali metal cations, alkaline earth metal cations, ammonium cations, quaternary ammonium cations and amine cations; and where at least one of R2, R3, R5 and R7 is a sulfur or phosphate containing group; where Y is an optional linker, Z is a multivalent support, and p is an integer in the range of 1-2000 inclusive.

  本发明涉及用于抑制配体和受体相互作用的组合物和方法。具体而言，提供了用于抑制病毒（特别是HIV）与受体之间相互作用的组合物和方法。抑制此类配体/受体相互作用有助于抑制细胞感染病毒。此外，配体/受体相互作用的抑制剂可作为体外或体内抑制测定的标准。在一个特定实施例中，根据本发明的组合物包括具有以下结构的化合物：[(X)—(Y)] p -Z，其中X为1，Q1和Q2分别独立地为H、与Y的键或与Z的键，其中Q1或Q2中至少有一个是与Y的键或与Z的键；R1、R4、R6和R8各自为H；R2、R3和R5各自独立地为OH、OSO3D或OPO3D，R7为CH20H、CH2OSO3D或CH2OPO3D；D为H或从以下群组中选择的阳离子：碱金属阳离子、碱土金属阳离子、铵阳离子、季铵阳离子和胺阳离子；其中R2、R3、R5和R7中至少有一个是含硫或磷酸酯基团；Y为可选的连接剂，Z为多价支持体，p为在1-2000范围内的整数。
• [EN] SULFATED GLYCOPOLYMERS<br/>[FR] GLYCOPOLYMÈRES SULFATÉS
  申请人：UNIV NOTTINGHAM

  公开号：WO2018007827A1

  公开（公告）日：2018-01-11

  This invention relates to sulfated glycopolymers comprising a polymeric backbone wherein at least one of the monomeric units which form the backbone has a pendant galactose and/or N-acetyl galactosamine group, wherein one or more of the pendant galactose groups are sulfated at one or more of positions 2, 3, 4 and 6 and/or one or more of the N-acetyl galactosamine groups are sulfated at one or more of positions 3, 4 and 6. The invention also relates to the use of sulfated glycopolymers in the treatment of a disease, for example, IRI, acute kidney injury, myocardial ischaemia, ischaemic stroke, cancer or an autoimmune disease.

  该发明涉及含有聚合骨架的磺酸基糖聚合物，其中形成骨架的单体单元中至少有一个带有半乳糖和/或N-乙酰半乳糖胺基团，其中一个或多个半乳糖基在2、3、4和6位置之一或多个位置上被磺酸化和/或一个或多个N-乙酰半乳糖胺基在3、4和6位置之一或多个位置上被磺酸化。该发明还涉及将磺酸基糖聚合物用于治疗疾病，例如IRI、急性肾损伤、心肌缺血、缺血性中风、癌症或自身免疫疾病。
• [EN] POLYMERIC CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS POLYMÈRES ET LEURS UTILISATIONS
  申请人：FUNDACION DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIG PRINCIPE FELIPE

  公开号：WO2020193802A1

  公开（公告）日：2020-10-01

  The present invention relates to novel chemical entities comprising a polymeric carrier incorporating covalently linked drug(s) as well as their pharmaceutical compositions containing the said polymer-drug conjugates as pharmaceutical agents and their uses thereof in therapy and, more particularly, but not exclusively, to novel conjugates having attached thereto a targeting moiety, an imaging agent and one or more therapeutic agents to promote axonal growth and for the treatment of neurodegenerative and inflammatory diseases, central nervous system traumatic injuries and cancer.

  本发明涉及一种新型化学实体，包括将药物共价连接到聚合载体中的药物，以及包含所述聚合物-药物共轭物作为药物代理的药物组合物，以及它们在治疗中的用途，更具体地说，但不限于，涉及附有靶向基团、成像剂和一个或多个治疗剂的新型共轭物，用于促进轴突生长和治疗神经退行性和炎症性疾病、中枢神经系统创伤性损伤和癌症。
• Immunomodulating compositions for treatment of immune system disorders
  申请人：——

  公开号：US20010009680A1

  公开（公告）日：2001-07-26

  The present invention relates to a composition for use as an immunomodulator comprising small molecular weight components of less than 3000 daltons, and having the following properties: a) is extractable from bile of animals; b) is capable of stimulating monocytes and macrophages in vitro and in vivo; c) is capable of modulating tumor necrosis factor production; d) contains no measurable IL-1&agr;, IL-1&bgr;, TNF, IL-6, IL-8, IL-4, GM-CSF or IFN-&ggr;; e) has an anti-proliferative effect in a malignant mouse hybridoma cell line; f) shows no cytotoxicity to human peripheral blood mononuclear cells or lymphocytes; and g) is not an endotoxin. The invention also relates to a method of preparing the composition, its use as an immunomodulator, and its use in the treatment of diseases and conditions having an immunological component.

  本发明涉及一种用作免疫调节剂的组合物，包括小分子量成分，分子量小于3000道尔顿，并具有以下特性：a）可从动物的胆汁中提取；b）能够在体外和体内刺激单核细胞和巨噬细胞；c）能够调节肿瘤坏死因子的产生；d）不含可测量的IL-1α、IL-1β、TNF、IL-6、IL-8、IL-4、GM-CSF或IFN-γ；e）对恶性小鼠杂交瘤细胞系具有抗增殖作用；f）对人类外周血单核细胞或淋巴细胞没有细胞毒性；g）不是内毒素。该发明还涉及一种制备该组合物的方法，其用作免疫调节剂，并在治疗具有免疫成分的疾病和病况中的应用。